# Akili Interactive Labs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akili-interactive-labs

- Industry: Healthcare IT
- Headquarters: Boston, US
- Website: www.akiliinteractive.com
- Total disclosed funding: $224M
- Latest round: Series D (May 26, 2021)
- Investors on record: 21

## About

Established in 2011 and based in Massachusetts, US, Akili Interactive Labs, Inc. also known as Akili, develops clinically-validated digital medicine for cognitive assessment and personalized treatment. Adam Gazzaley, Eddie Martucci, and Matthew Omernick are the co-founders of the company. In May 2021, the firm raised USD 50 million in venture debt financing from SVB Capital.

The company's product, EndeavorRx® is a prescription treatment delivered through a video game that improves attention to function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. The product presents specific sensory stimuli and simultaneous motor challenges designed to target neural systems in the brain related to attentional control.

Akili will use the May 2021 funding to expand its global footprint and fund 
research across a wide range of cognitive impairments.

## Funding rounds

- Series D, May 26, 2021, $110M — Temasek Holdings, Polaris Partners, Amgen Ventures, Mirae Asset Global Investments, New Leaf Venture Partners, Shionogi Pharmaceutical, Neuberger Berman, Evidity Health Capital, JAZZ Venture Partners, Omidyar Technology Ventures, M Ventures, Fearless Ventures, QUAD Ventures, Baillie Gifford, Ladera Venture Partners
- Series C, Aug 9, 2018, $13M — CLSA Capital Partners, DG Ventures, Omidyar Technology Ventures, Fearless Ventures, DG Daiwa Ventures
- Series C, May 8, 2018, $55M — Temasek Holdings, Amgen Ventures, Baillie Gifford, Evidity Health Capital, JAZZ Venture Partners, Brooklands Capital Strategies
- Series B, Jul 20, 2016, $12M — Amgen Ventures, M Ventures
- Series B, Jan 22, 2016, $31M — Evidity Health Capital, PureTech Health plc, JAZZ Venture Partners
- Series A, Feb 19, 2012, $4M — Walnut Venture Associates

## Investors

- Walnut Venture Associates (https://capitalatlas.ai/funds/walnut-venture-associates) — Series A
- Evidity Health Capital (https://capitalatlas.ai/funds/evidity-health-capital) — Series B, Series C, Series D
- PureTech Health plc — Series B
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series B, Series C, Series D
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B, Series C, Series D
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series B, Series D
- Temasek Holdings — Series C, Series D
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series C, Series D
- Brooklands Capital Strategies (https://capitalatlas.ai/funds/brooklands-capital-strategies) — Series C
- CLSA Capital Partners (https://capitalatlas.ai/funds/clsa-capital-partners) — Series C
- DG Ventures (https://capitalatlas.ai/funds/dg-ventures) — Series C
- Omidyar Technology Ventures (https://capitalatlas.ai/funds/omidyar-technology-ventures) — Series C, Series D
- Fearless Ventures (https://capitalatlas.ai/funds/fearless-ventures) — Series C, Series D
- DG Daiwa Ventures (https://capitalatlas.ai/funds/dg-daiwa-ventures) — Series C
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series D
- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series D
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series D
- Shionogi Pharmaceutical — Series D
- Neuberger Berman (https://capitalatlas.ai/funds/neuberger-berman) — Series D
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series D
- Ladera Venture Partners (https://capitalatlas.ai/funds/ladera-venture-partners) — Series D